Navigation Links
Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
Date:12/8/2011

eutical company developing novel oncology compounds that target cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinically active compounds, both of which have demonstrated durable complete responses (CRs) and an overall survival (OS) benefit in Phase I/II studies. SL-401 has completed a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) where it has demonstrated single agent activity, including two durable CRs and an OS benefit, in heavily pretreated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. SL-401 is also currently being tested in additional indications including chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). The Company's second clinical program, SL-701, has demonstrated single agent activity including durable tumor responses, which includes CRs, multiple partial responses (PRs) and an OS benefit, in Phase I/II trials of adult patients with refractory or recurrent high grade glioma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:
Mark Jacobson
Associate Director, Business Development
Stemline Therapeutics, Inc.
Tel: 212-584-5747
Email: mjacobson@stemline.com

This announcement contains forward-looking statements relating to Stemline's business, which are based on the Company's current expectations concerning future d
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
6. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
7. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
8. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
9. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
10. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
11. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The global ... of 22.3% during the forecast period of 2015 to ... increasingly being used in drug discovery and development process ... market growth. In addition to this,heavy investments by key ... applications are also propelling market growth. Browse 113 market ...
(Date:5/20/2015)... NEW YORK , May 20, 2015 /PRNewswire-USNewswire/ ... announced a leadership gift of $100 million from ... help create a new laboratory building that will ... campus extension. The Marie-Josée and Henry R. Kravis ... over the FDR Drive, spanning approximately three city ...
(Date:5/20/2015)... -- Resolution Bioscience announced today the successful results from their ... blood-based liquid biopsy for an ALK-gene fusion driver mutation ... common form of this cancer. Researchers or clinicians can ... therapies and direct them into clinical trials with a ... the CLIA authority in Washington State ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... , , , ... today it has signed a provider agreement with Beech Street ... for healthcare management services. Beech Street will assist SpectraCell with ... an expanding laboratory. , , ...
... , HORSHAM, Pa., Sept. ... it received a Complete Response letter from the U.S. Food ... for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI ... women with relapsed ovarian cancer. The agency has requested ...
... NEW YORK, Sept. 10 David C. Galloway is recognized ... He provides Genealogy Consulting Services as well as Chemistry Laboratory ... David,s Genealogy Services Company has found much success due to ... David is responsible for all Analytical Proceedings as well as ...
Cached Biology Technology:SpectraCell Contracts With Beech Street Corporation 2FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL 2Continental Who's Who Executive Press Release: David C. Galloway 2
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... , EAST LANSING, Mich. -- You,d be amazed at how much ... this week in the journal Science , a Michigan State ... survive as a species, we must turn more to plants for ... with fiber, fuel, food and therapeutics," said Robert Last, an MSU ...
... device about the size of a dime can manipulate living ... sound waves, according to a team of bioengineers and biochemists ... the first technology capable of touchlessly trapping and manipulating ... long roundworm that is an important model system for studying ...
... at Boston University School of Medicine (BUSM) revealed that ... the pathological mechanisms of Parkinson,s disease. These findings are ... open-access journal published by the Public Library of Science. ... a postdoctoral associate in the department of neurology at ...
Cached Biology News:Scientists urge new approaches to plant research 2Acoustic tweezers capture tiny creatures with ultrasound 2BUSM researchers identify role of FOXO1 gene in Parkinson's disease 2
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... The desk-top XCAT 50 X-Ray System from KUBTEC ... to provide two and three dimensional representation of ... provides volumetric reconstruction of specimen X-ray images, the ... provide high level of detail in standard 2D ...
... BTX, the leader in electroporation products and ... innovative product line for experiment optimization and ... is a breakthrough in Molecular Delivery. The ... procedures that typically limited the number of ...
... PolarScreen Progesterone Receptor (PR) Competitor Assay ... screening novel progesterone receptor binding compounds ... assay utilizes a fusion of glutathione ... of human progesterone receptor [PR-LBD(GST)] and ...
Biology Products: